Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CRNX Stock Forecast

Crinetics Pharmaceuticals stock forecast is as follows: an average price target of $70.14 (represents a 22.99% upside from CRNX’s last price of $57.03) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

CRNX Price Target

The average price target for Crinetics Pharmaceuticals (CRNX) is $70.14 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $97.00 to $39.00. This represents a potential 22.99% upside from CRNX's last price of $57.03.

CRNX Analyst Ratings

Buy

According to 6 Wall Street analysts, Crinetics Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CRNX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Crinetics Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 09, 2024	Douglas Tsao	H.C. Wainwright	$69.00	$50.74	35.99%	20.99%
Jun 04, 2024	Leland Gershell	Oppenheimer	$74.00	$46.28	59.90%	29.76%
May 23, 2024	Brian Skorney	Robert W. Baird	$62.00	$49.13	26.20%	8.71%
May 22, 2024	Jeffrey Hung	Morgan Stanley	$70.00	$50.54	38.50%	22.74%
May 07, 2024	Yasmeen Rahimi	Piper Sandler	$97.00	$47.47	104.34%	70.09%
Mar 20, 2024	Jonathan Wolleben	JMP Securities	$80.00	$45.49	75.86%	40.28%
Mar 13, 2024	Leland Gershell	Oppenheimer	$54.00	$40.50	33.33%	-5.31%
Aug 31, 2023	Leland Gershell	Oppenheimer	$40.00	$17.43	129.49%	-29.86%
May 26, 2022	-	Leerink Partners	$39.00	$17.37	124.53%	-31.61%

Row per page

Go to

The latest Crinetics Pharmaceuticals stock forecast, released on Aug 09, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $69.00, which represents a 35.99% increase from the stock price at the time of the forecast ($50.74), and a 20.99% increase from CRNX last price ($57.03).

Crinetics Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	7
Avg Price Target	-	-	$72.29
Last Closing Price	$57.03	$57.03	$57.03
Upside/Downside	-100.00%	-100.00%	26.76%

In the current month, the average price target of Crinetics Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Crinetics Pharmaceuticals's last price of $57.03. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 27, 2024	Oppenheimer	Underperform	Underperform	Hold
Sep 27, 2024	Piper Sandler	Market Outperform	Market Outperform	Hold
Sep 27, 2024	Piper Sandler	Overweight	Overweight	Hold
Aug 09, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 02, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 28, 2024	Oppenheimer	Underperform	Underperform	Hold
Jun 28, 2024	Piper Sandler	Market Outperform	Market Outperform	Hold
Jun 04, 2024	Oppenheimer	Underperform	Underperform	Hold
Jun 04, 2024	Piper Sandler	Buy	Buy	Hold
Jun 04, 2024	Piper Sandler	Overweight	Overweight	Hold

Row per page

Go to

Crinetics Pharmaceuticals's last stock rating was published by Oppenheimer on Sep 27, 2024. The company gave CRNX a "Underperform" rating, the same as its previous rate.

Crinetics Pharmaceuticals Financial Forecast

Crinetics Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$988.00K	$2.68M	$709.00K	$458.00K	$439.00K	$3.13M	$71.00K	$321.00K	$505.00K	-	$367.00K	$657.00K
Avg Forecast	$13.99M	$10.13M	$7.19M	$5.50M	$3.97M	$430.43K	$761.00K	$71.29K	$672.64K	$218.09K	$467.27K	$200.00K	$197.10K	$1.10M	$254.25K	$250.00K	$250.00K	$600.00K	$5.20M	$63.00K	$130.00K	$150.00K	$187.50K	$130.00K	$3.73M
High Forecast	$20.42M	$14.79M	$10.50M	$8.02M	$5.79M	$628.11K	$1.11M	$104.02K	$1.01M	$218.14K	$467.41K	$291.85K	$307.97K	$1.60M	$371.01K	$364.81K	$250.00K	$600.00K	$5.20M	$75.60K	$130.00K	$150.00K	$187.50K	$130.00K	$4.48M
Low Forecast	$7.57M	$5.48M	$3.89M	$2.97M	$2.14M	$232.75K	$411.50K	$38.55K	$339.01K	$218.04K	$467.14K	$108.15K	$92.39K	$593.19K	$137.48K	$135.19K	$250.00K	$600.00K	$5.20M	$50.40K	$130.00K	$150.00K	$187.50K	$130.00K	$2.99M
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	4	4	4	4	9	7	4	3	13	15
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.90%	10.54%	2.84%	1.83%	0.73%	0.60%	1.13%	2.47%	3.37%	-	2.82%	0.18%

Crinetics Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 6 analysts is $197.10K, with a low forecast of $92.39K, and a high forecast of $307.97K. CRNX's average Quarter revenue forecast represents a -80.05% decrease compared to the company's last Quarter revenue of $988.00K (Jun 23).

Crinetics Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	4	4	4	4	9	7	4	3	13	15
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-52.72M	$-47.98M	$-47.56M	$-43.21M	$-42.86M	$-33.59M	$-17.13M	$-14.32M	$-14.20M	$-12.25M	$-8.76M	$-5.49M
Avg Forecast	$-13.99M	$-10.13M	$-7.19M	$-5.50M	$-3.97M	$-430.43K	$-761.00K	$-71.29K	$-672.64K	$-218.09K	$-467.27K	$-200.00K	$-197.10K	$-1.10M	$-254.25K	$-250.00K	$-250.00K	$-600.00K	$-25.35M	$-14.95M	$-130.00K	$-150.00K	$-187.50K	$-9.62M	$-31.19M
High Forecast	$-7.57M	$-5.48M	$-3.89M	$-2.97M	$-2.14M	$-232.75K	$-411.50K	$-38.55K	$-339.01K	$-218.04K	$-467.14K	$-108.15K	$-92.39K	$-593.19K	$-137.48K	$-135.19K	$-250.00K	$-600.00K	$-20.28M	$-11.96M	$-130.00K	$-150.00K	$-187.50K	$-7.69M	$-24.95M
Low Forecast	$-20.42M	$-14.79M	$-10.50M	$-8.02M	$-5.79M	$-628.11K	$-1.11M	$-104.02K	$-1.01M	$-218.14K	$-467.41K	$-291.85K	$-307.97K	$-1.60M	$-371.01K	$-364.81K	$-250.00K	$-600.00K	$-30.42M	$-17.94M	$-130.00K	$-150.00K	$-187.50K	$-11.54M	$-37.43M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	48.05%	188.70%	190.22%	172.82%	71.44%	1.32%	1.15%	110.15%	94.68%	65.33%	0.91%	0.18%

undefined analysts predict CRNX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Crinetics Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Crinetics Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	4	4	4	4	9	7	4	3	13	15
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-50.98M	$-44.01M	$-42.43M	$-40.40M	$-41.70M	$-35.43M	$-17.36M	$-14.55M	$-14.43M	$-12.43M	$-9.02M	$-5.57M
Avg Forecast	$-90.50M	$-88.50M	$-86.50M	$-84.10M	$-90.50M	$-88.30M	$-81.79M	$-76.79M	$-72.79M	$-72.94M	$-68.79M	$-64.84M	$-69.08M	$-69.32M	$-66.09M	$-65.90M	$-61.99M	$-50.68M	$-25.67M	$-15.16M	$-53.46M	$-44.88M	$-36.03M	$-9.90M	$-31.62M
High Forecast	$-36.47M	$-35.66M	$-34.86M	$-33.89M	$-36.47M	$-35.58M	$-32.96M	$-67.99M	$-61.95M	$-29.39M	$-27.72M	$-26.13M	$-62.87M	$-27.93M	$-26.63M	$-26.56M	$-61.99M	$-50.68M	$-20.54M	$-12.12M	$-53.46M	$-44.88M	$-36.03M	$-7.92M	$-25.30M
Low Forecast	$-144.54M	$-141.34M	$-138.14M	$-134.30M	$-144.54M	$-141.02M	$-130.63M	$-95.98M	$-89.06M	$-116.48M	$-109.86M	$-103.55M	$-77.62M	$-110.71M	$-105.55M	$-105.25M	$-61.99M	$-50.68M	$-30.81M	$-18.19M	$-53.46M	$-44.88M	$-36.03M	$-11.87M	$-37.95M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.74%	0.67%	0.64%	0.65%	0.82%	1.38%	1.15%	0.27%	0.32%	0.34%	0.91%	0.18%

Crinetics Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRNX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Crinetics Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	4	4	4	4	9	7	4	3	13	15
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$13.34M	$12.19M	$11.27M	$11.93M	$10.49M	$8.71M	$3.99M	$3.39M	$3.91M	$3.06M	$3.16M	$1.12M
Avg Forecast	$871.53M	$631.07M	$448.04M	$342.22M	$246.94M	$26.81M	$47.39M	$4.44M	$41.89M	$13.58M	$29.10M	$12.46M	$12.28M	$68.32M	$15.83M	$15.57M	$15.57M	$37.37M	$323.85M	$3.92M	$8.10M	$9.34M	$11.68M	$8.10M	$232.38M
High Forecast	$1.27B	$920.90M	$653.80M	$499.39M	$360.36M	$39.12M	$69.16M	$6.48M	$62.67M	$13.59M	$29.11M	$18.18M	$19.18M	$99.70M	$23.11M	$22.72M	$15.57M	$37.37M	$323.85M	$4.71M	$8.10M	$9.34M	$11.68M	$8.10M	$278.86M
Low Forecast	$471.27M	$341.25M	$242.27M	$185.05M	$133.53M	$14.50M	$25.63M	$2.40M	$21.11M	$13.58M	$29.09M	$6.74M	$5.75M	$36.94M	$8.56M	$8.42M	$15.57M	$37.37M	$323.85M	$3.14M	$8.10M	$9.34M	$11.68M	$8.10M	$185.91M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.20%	0.77%	0.72%	0.77%	0.28%	0.03%	1.02%	0.42%	0.42%	0.26%	0.39%	0.00%

Crinetics Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $12.28M, based on 6 Wall Street analysts, with a range of $5.75M to $19.18M. The forecast indicates a -8.00% fall compared to CRNX last annual SG&A of $13.34M (Jun 23).

Crinetics Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
# Analysts	2	2	2	2	1	1	1	4	6	3	3	3	6	3	3	4	4	4	4	9	7	4	3	13	15
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.94	$-0.82	$-0.79	$-0.75	$-0.79	$-0.74	$-0.71	$-0.60	$-0.60	$-0.51	$-0.37	$-0.25
Avg Forecast	$-1.13	$-1.10	$-1.08	$-1.05	$-1.13	$-1.10	$-1.02	$-0.96	$-0.91	$-0.91	$-0.86	$-0.81	$-0.86	$-0.87	$-0.83	$-0.82	$-0.78	$-0.64	$-0.58	$-0.63	$-0.68	$-0.57	$-0.46	$-0.41	$-1.65
High Forecast	$-0.46	$-0.45	$-0.44	$-0.42	$-0.46	$-0.44	$-0.41	$-0.85	$-0.77	$-0.37	$-0.35	$-0.33	$-0.79	$-0.35	$-0.33	$-0.33	$-0.78	$-0.64	$-0.58	$-0.63	$-0.68	$-0.57	$-0.46	$-0.41	$-1.32
Low Forecast	$-1.80	$-1.76	$-1.72	$-1.68	$-1.80	$-1.76	$-1.63	$-1.20	$-1.11	$-1.45	$-1.37	$-1.29	$-0.97	$-1.38	$-1.32	$-1.31	$-0.78	$-0.64	$-0.58	$-0.63	$-0.68	$-0.57	$-0.46	$-0.41	$-1.98
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.09%	0.99%	0.96%	0.96%	1.23%	1.28%	1.13%	0.89%	1.06%	1.12%	0.90%	0.15%

According to undefined Wall Street analysts, Crinetics Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRNX previous annual EPS of $NaN (undefined).

Crinetics Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.54	$6.00	1011.11%	Buy
LYEL	Lyell Immunopharma	$0.92	$6.67	625.00%	Hold
BDTX	Black Diamond Therapeutics	$2.43	$14.75	507.00%	Buy
RGNX	REGENXBIO	$9.18	$32.00	248.58%	Buy
GPCR	Structure Therapeutics	$30.10	$92.40	206.98%	Buy
KZR	Kezar Life Sciences	$7.62	$17.50	129.66%	Buy
VRDN	Viridian Therapeutics	$19.62	$37.92	93.27%	Buy
KRON	Kronos Bio	$0.87	$1.63	87.36%	Buy
CYTK	Cytokinetics	$47.67	$83.23	74.60%	Buy
MRUS	Merus	$44.36	$76.67	72.84%	Buy
CRNX	Crinetics Pharmaceuticals	$57.03	$70.14	22.99%	Buy
ALEC	Alector	$3.76	$4.00	6.38%	Buy

CRNX Forecast FAQ

Is Crinetics Pharmaceuticals a good buy?

Yes, according to 6 Wall Street analysts, Crinetics Pharmaceuticals (CRNX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CRNX's total ratings.

What is CRNX's price target?

Crinetics Pharmaceuticals (CRNX) average price target is $70.14 with a range of $39 to $97, implying a 22.99% from its last price of $57.03. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Crinetics Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for CRNX stock, the company can go up by 22.99% (from the last price of $57.03 to the average price target of $70.14), up by 70.09% based on the highest stock price target, and down by -31.61% based on the lowest stock price target.

Can Crinetics Pharmaceuticals stock reach $90?

CRNX's highest twelve months analyst stock price target of $97 supports the claim that Crinetics Pharmaceuticals can reach $90 in the near future.

What are Crinetics Pharmaceuticals's analysts' financial forecasts?

Crinetics Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.23M (high $7.63M, low $2.83M), average EBITDA is $-5.228M (high $-2.827M, low $-7.629M), average net income is $-337M (high $-173M, low $-512M), average SG&A $325.59M (high $475.11M, low $176.06M), and average EPS is $-4.213 (high $-2.16, low $-6.395). CRNX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $36.82M (high $53.72M, low $19.91M), average EBITDA is $-36.816M (high $-19.908M, low $-53.724M), average net income is $-350M (high $-141M, low $-558M), average SG&A $2.29B (high $3.35B, low $1.24B), and average EPS is $-4.365 (high $-1.759, low $-6.971).

Did the CRNX's actual financial results beat the analysts' financial forecasts?

Based on Crinetics Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $4.74M, which missed the average analysts forecast of $6.3M by -24.81%. Apple's EBITDA was $-168M, beating the average prediction of $-26.451M by 534.70%. The company's net income was $-160M, missing the average estimation of $-204M by -21.68%. Apple's SG&A was $42.39M, missing the average forecast of $392.36M by -89.20%. Lastly, the company's EPS was $-3.08, beating the average prediction of $-2.829 by 8.88%. In terms of the last quarterly report (Jun 2023), Crinetics Pharmaceuticals's revenue was $988K, missing the average analysts' forecast of $1.1M by -9.94%. The company's EBITDA was $-52.715M, beating the average prediction of $-1.097M by 4705.38%. Crinetics Pharmaceuticals's net income was $-50.979M, missing the average estimation of $-69.324M by -26.46%. The company's SG&A was $13.34M, missing the average forecast of $68.32M by -80.47%. Lastly, the company's EPS was $-0.94, beating the average prediction of $-0.866 by 8.60%